Explainer
Who can get a COVID vaccine in 2026-27
In the United States the 2026-2027 COVID-19 vaccines are approved for everyone 65 and older and for younger people with at least one condition that puts them at high risk of severe COVID-19, from age 5 for Comirnaty, 6 months for Spikevax and 12 for mNEXSPIKE.[1] The FDA first narrowed approvals to those groups in August 2025 and kept that scope when it approved the XFG-targeted 2026-2027 formulas on 27 August 2026.[2][3] Separately, ACIP voted in September 2025 for shared clinical decision-making for COVID-19 vaccination, a federal court stayed the committee's votes in March 2026, and an August 2026 executive order lists COVID-19 vaccination as a shared decision for children.[4][5][6]
This page explains who the US COVID-19 vaccines are approved for and what official bodies have recommended, attributed to each. It is not medical advice and gives no doses: ask a clinician or pharmacist whether a COVID-19 vaccine is right for you, and check with your pharmacy and state, as access rules vary.
In the United States, the 2026-2027 COVID-19 vaccines are approved for everyone 65 and older and for younger people with at least one underlying condition that puts them at high risk of severe COVID-19.[1] That is narrower than before August 2025, and federal recommendations have been in flux since ACIP’s membership changed in 2025.[2][7]
What the FDA approvals cover
After its vaccine advisers met on 28 May 2026, the FDA advised manufacturers that 2026-2027 vaccines should target the JN.1-lineage XFG variant.[8] On 27 August 2026 it approved 2026-2027 formula versions of Comirnaty, Spikevax and mNEXSPIKE, and Novavax’s protein-based Nuvaxovid was also approved for the season.[3] The mRNA vaccines are approved for everyone 65 and older and for people with at least one high-risk condition from age 5 for Comirnaty, 6 months for Spikevax and 12 years for mNEXSPIKE.[1] For how these vaccines work, see how mRNA vaccines work.
Why eligibility narrowed in 2025
In August 2025 the FDA limited the approved use of Comirnaty to people 65 and older and younger people with at least one condition that puts them at high risk of severe COVID-19.[2] The memo by the director of its biologics centre concluded there was not substantial certainty of a net benefit from vaccinating healthy people with the mRNA vaccine, but that there was for people with risk factors.[9] Under the FDA’s framework, approval for healthy people requires randomized trials measuring clinical outcomes, and Pfizer-BioNTech agreed to a placebo-controlled trial in healthy adults aged 50 to 64.[10] The 2026-2027 approvals kept that narrower scope.[1] The wider debate is covered in the US mRNA vaccine policy debate.
ACIP, the courts and the executive order
On 19 September 2025 the reconstituted ACIP voted to recommend COVID-19 vaccination based on individual (shared clinical) decision-making for people 6 months and older, and rejected a proposal to require prescriptions.[4] On 16 March 2026 a federal court in Massachusetts stayed 13 ACIP appointments and all votes of the reconstituted committee since June 2025; the government has appealed.[5][11] An executive order of 10 August 2026 lists COVID-19 among childhood immunizations based on shared clinical decision-making.[6] The US vaccine schedule changes tracker records each step.
Medical societies, states and insurers
The American Academy of Pediatrics issues its own immunization recommendations and released updated COVID-19 and RSV guidance on 2 September 2026.[12] Some states follow AAP guidance through regional alliances; see state vaccine alliances explained.[13] The insurers’ group AHIP says member plans will cover all ACIP-recommended immunizations with no cost sharing through the end of 2027.[14]
Read next
State vaccine alliances explained: WCHA, the Northeast group and GPHA
What the West Coast Health Alliance, the Northeast Public Health Collaborative and the Governors Public Health Alliance are, who belongs and what they do.
Questions readers ask
Who is the 2026-2027 COVID-19 vaccine approved for?
The FDA approvals cover everyone 65 and older and younger people with at least one underlying condition that puts them at high risk of severe COVID-19. The lower age limit depends on the product - 5 years for Comirnaty, 6 months for Spikevax and 12 years for mNEXSPIKE.[1]
Which vaccines are available for 2026-27?
On 27 August 2026 the FDA approved 2026-2027 formula versions of the mRNA vaccines Comirnaty, Spikevax and mNEXSPIKE, which target the XFG variant, and Novavax's protein-based Nuvaxovid was also approved for the season.[3][8]
Why can't every healthy adult under 65 get it under the label?
The FDA narrowed the approvals in August 2025. A memo by the director of its biologics centre concluded there was not substantial certainty of net benefit from vaccinating healthy people with the mRNA vaccine, and the agency's framework requires randomized trials measuring clinical outcomes before approval for healthy people.[2][9][10]
What does ACIP recommend?
On 19 September 2025 ACIP voted for shared clinical decision-making for COVID-19 vaccination for people 6 months and older. In March 2026 a federal court stayed all votes of the reconstituted committee since June 2025, and the government has appealed.[4][5][11]
What about children?
The August 2026 executive order lists COVID-19 among immunizations based on shared clinical decision-making for children. The American Academy of Pediatrics publishes its own guidance and released updated COVID-19 recommendations on 2 September 2026.[6][12]
Will insurance cover it?
The insurers' group AHIP says member plans will cover all ACIP-recommended immunizations with no cost sharing through the end of 2027. Check with your plan for your own coverage.[14]
Sources
· 14 claims from 14 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
The 2026-2027 approvals kept the narrower US eligibility set in 2025, covering everyone 65 and older plus younger people with at least one high-risk condition, from age 5 for Comirnaty, 6 months for Spikevax and 12 for mNEXSPIKE. confirmedas of 2026-08-28
- COMIRNATY (product page and approval history) · US Food and Drug Administration · Primary source (retrieved 2026-10-10)
- SPIKEVAX (product page and approval history) · US Food and Drug Administration · Primary source (retrieved 2026-10-10)
- MNEXSPIKE (product page and approval history) · US Food and Drug Administration · Primary source (retrieved 2026-10-10)
- FDA approves updated Covid-19 vaccines · CNN · Secondary source · 2026-08-27 (retrieved 2026-10-10)
- [2]
In August 2025 the FDA limited the approved use of Pfizer-BioNTech's Comirnaty to people 65 and older and younger people with at least one condition that puts them at high risk of severe COVID-19. confirmedas of 2025-08-25
- CBER Center Director Decisional Memo: COMIRNATY sBLA (August 25, 2025) · US Food and Drug Administration · Primary source · 2025-08-25 (retrieved 2026-10-10)
- FDA Approves COVID-19 Vaccines With Postmarketing Study Strings Attached · Managed Healthcare Executive · Secondary source · 2025-08-27 (retrieved 2026-10-10)
- [3]
On 27 August 2026 the FDA approved 2026-2027 formula versions of the mRNA vaccines Comirnaty, Spikevax and mNEXSPIKE, which target the XFG variant; Novavax's protein-based Nuvaxovid was also approved for the season. confirmedas of 2026-08-27
- COMIRNATY supplement approval letter (2026-2027 Formula), August 27, 2026 · US Food and Drug Administration · Primary source · 2026-08-27 (retrieved 2026-10-10)
- MNEXSPIKE supplement approval letter (2026-2027 Formula), August 27, 2026 · US Food and Drug Administration · Primary source · 2026-08-27 (retrieved 2026-10-10)
- SPIKEVAX (product page and approval history) · US Food and Drug Administration · Primary source (retrieved 2026-10-10)
- FDA approves updated Covid-19 vaccines · CNN · Secondary source · 2026-08-27 (retrieved 2026-10-10)
- [4]
On 19 September 2025 ACIP voted to recommend COVID-19 vaccination based on individual-based (shared clinical) decision-making for people 6 months and older, and rejected a proposal to require prescriptions. confirmedas of 2025-09-19
- ACIP COVID Vaccine Recommendations: Shared Clinical Decision-Making, No Prescriptions · LeadingAge · Secondary source · 2025-09-19 (retrieved 2026-10-10)
- ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making · Pharmacy Times · Secondary source · 2025-09-19 (retrieved 2026-10-10)
- Brief for Federal Defendants-Appellants, AAP v. Kennedy, No. 26-1503 (1st Cir.) · US Department of Justice (court filing, hosted by Courthouse News) · Primary source · 2026-06-18 · Addendum, district court opinion (PI Op. at 9); brief p. 9 says the same (retrieved 2026-10-10)
- [5]
On 16 March 2026 a federal district court in Massachusetts, in American Academy of Pediatrics v. Kennedy, stayed the 13 ACIP appointments and all votes of the reconstituted committee since June 2025. confirmedas of 2026-03-17
- Brief for Federal Defendants-Appellants, AAP v. Kennedy, No. 26-1503 (1st Cir.) · US Department of Justice (court filing, hosted by Courthouse News) · Primary source · 2026-06-18 · Statement of the case, pp. 11-12 ("On March 16, 2026, the district court granted the preliminary injunction motion in part."); cover: "United States District Court for the District of Massachusetts" (retrieved 2026-10-10)
- The State of US Vaccine Policy: Special Edition - Mar 17, 2026 · CIDRAP (University of Minnesota) · Secondary source · 2026-03-17 (retrieved 2026-10-10)
- Judge Pauses Pediatricians' Lawsuit Over Kennedy's Vaccine Changes as Families Await October 6 Appeals Court Argument · Medical Daily · Secondary source · 2026-09-15 (retrieved 2026-10-10)
- [6]
Executive Order 14420 of 10 August 2026 declared "Gold Standard Childhood Vaccine Recommendations" listing immunizations recommended for all children against 11 diseases (measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Hib, pneumococcal disease, HPV and varicella), risk-based recommendations for RSV antibodies, hepatitis A and B, MenB, MenACWY and dengue, and shared clinical decision-making for hepatitis A and B, rotavirus, meningococcal disease, influenza and COVID-19. confirmedas of 2026-08-14
- Executive Order 14420: Delivering Gold Standard Childhood Vaccine Recommendations for Americans · Federal Register · Primary source · 2026-08-14 (retrieved 2026-11-07)
- Executive Order 14420: Delivering Gold Standard Childhood Vaccine Recommendations for Americans · Federal Register · Primary source · 2026-08-14 (retrieved 2026-11-07)
- Executive Order 14420: Delivering Gold Standard Childhood Vaccine Recommendations for Americans · Federal Register · Primary source · 2026-08-14 (retrieved 2026-11-07)
- [7]
After Secretary Kennedy removed the existing ACIP members in June 2025, 13 of the 15 members serving by early 2026 had been appointed between June 2025 and January 2026. confirmedas of 2026-03-17
- FDA Approves COVID-19 Vaccines With Postmarketing Study Strings Attached · Managed Healthcare Executive · Secondary source · 2025-08-27 (retrieved 2026-10-10)
- The State of US Vaccine Policy: Special Edition - Mar 17, 2026 · CIDRAP (University of Minnesota) · Secondary source · 2026-03-17 (retrieved 2026-10-10)
- Brief for Federal Defendants-Appellants, AAP v. Kennedy, No. 26-1503 (1st Cir.) · US Department of Justice (court filing, hosted by Courthouse News) · Primary source · 2026-06-18 · Statement of the case, p. 8 ("On June 11, the Secretary announced eight replacement appointments.") (retrieved 2026-10-10)
- [8]
After its vaccine advisory committee met on 28 May 2026, the FDA advised manufacturers that 2026-2027 COVID-19 vaccines for the US should be monovalent vaccines targeting the JN.1-lineage XFG variant. confirmedas of 2026-05-29
- COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beginning in Fall 2026 · US Food and Drug Administration · Primary source · 2026-05-29 (retrieved 2026-10-10)
- COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beginning in Fall 2026 · US Food and Drug Administration · Primary source · 2026-05-29 (retrieved 2026-10-10)
- [9]
The FDA biologics center director's August 2025 memo concluded there was not substantial certainty of net benefit from vaccinating healthy people with the mRNA vaccine, but that there was for people with risk factors. confirmedas of 2025-08-25
- CBER Center Director Decisional Memo: COMIRNATY sBLA (August 25, 2025) · US Food and Drug Administration · Primary source · 2025-08-25 (retrieved 2026-10-10)
- [10]
Under the FDA framework, approval for healthy people requires randomized trials measuring clinical outcomes; Pfizer-BioNTech agreed to a saline placebo-controlled trial in healthy adults aged 50-64. confirmedas of 2025-08-25
- CBER Center Director Decisional Memo: COMIRNATY sBLA (August 25, 2025) · US Food and Drug Administration · Primary source · 2025-08-25 (retrieved 2026-10-10)
- FDA Approves COVID-19 Vaccines With Postmarketing Study Strings Attached · Managed Healthcare Executive · Secondary source · 2025-08-27 (retrieved 2026-10-10)
- [11]
The federal government appealed the March 2026 ruling to the First Circuit (No. 26-1503), and district court proceedings were paused pending the appeal. confirmedas of 2026-09-30
- American Academy of Pediatrics et al. v. Kennedy et al. - Health Care Litigation Tracker · Georgetown Law O'Neill Institute · Secondary source (retrieved 2026-10-10)
- Judge Pauses Pediatricians' Lawsuit Over Kennedy's Vaccine Changes as Families Await October 6 Appeals Court Argument · Medical Daily · Secondary source · 2026-09-15 (retrieved 2026-10-10)
- Brief for Federal Defendants-Appellants, AAP v. Kennedy, No. 26-1503 (1st Cir.) · US Department of Justice (court filing, hosted by Courthouse News) · Primary source · 2026-06-18 (retrieved 2026-10-10)
- [12]
The American Academy of Pediatrics issues its own evidence-based immunization recommendations and an annually updated schedule; it released updated COVID-19 and RSV guidance on 2 September 2026 and plans its 2027 child and adolescent schedule for January 2027. confirmedas of 2026-11-04
- AAP Immunization Recommendations Process: 2026 · American Academy of Pediatrics · Primary source (retrieved 2026-11-07)
- AAP Immunization Recommendations Process: 2026 · American Academy of Pediatrics · Primary source (retrieved 2026-11-07)
- AAP Immunization Recommendations Process: 2026 · American Academy of Pediatrics · Primary source (retrieved 2026-11-07)
- [13]
On 26 January 2026 California's health department and the West Coast Health Alliance endorsed the AAP's 2026 child and adolescent schedule, which they said differs from recent CDC changes, and California said it will keep adopting the most recent AAP recommendations. confirmedas of 2026-01-26
- West Coast Health Alliance Endorses Annual Update of American Academy of Pediatrics Vaccine Schedule · California Department of Public Health · Primary source · 2026-01-26 (retrieved 2026-11-14)
- West Coast Health Alliance Endorses Annual Update of American Academy of Pediatrics Vaccine Schedule · California Department of Public Health · Primary source · 2026-01-26 (retrieved 2026-11-14)
- [14]
The insurers' trade group AHIP said in December 2025 that member plans would keep covering immunizations ACIP recommended as of 1 September 2025, and its statement, updated as of May 2026, says plans will cover all ACIP-recommended immunizations with no cost sharing through the end of 2027. confirmedas of 2026-11-07
- AHIP Statement on Vaccine Coverage · AHIP · Primary source · 2025-09-16 · Statement first published 16 September 2025; page marked "Updated as of May 2026". (retrieved 2026-11-07)
- Medical groups decry CDC's decision to upend hepatitis B vaccine endorsement · Fierce Healthcare · Secondary source · 2025-12-17 (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: May 7, 2027.
Cite this page
"Who can get a COVID vaccine in 2026-27." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/covid-vaccine-eligibility-2026-27
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.